ZNF671 methylation test in cervical scrapings for cervical intraepithelial neoplasia grade 3 and cervical cancer detection

Cell Rep Med. 2023 Aug 15;4(8):101143. doi: 10.1016/j.xcrm.2023.101143. Epub 2023 Aug 8.

Abstract

Effective triage of high-risk human papillomavirus (hrHPV)+ women is warranted to avoid unnecessary referral and overtreatment. Molecular triage tests have recently begun to impact cervical intraepithelial neoplasia grade 3 (CIN3) or cervical cancer (CC), termed CIN3+, detection. We find that zinc finger protein 671 methylation (ZNF671m) test has superior performance for CIN3+ detection in all single molecular triage tests, including HPV16/18 genotyping, paired box gene 1 methylation (PAX1m), and ZNF671m, in the training set. Using ZNF671m test instead of Thinprep cytologic test (TCT) as a single triage strategy or as a combined triage strategy with HPV16/18 genotyping has achieved comparable sensitivity but higher specificity for CIN3+ detection among 391 hrHPV+ women in the validation set. Little attention has been paid to the women with hrHPV- status but detected CIN3+. We find that the CIN3+ risk after a negative result could be reduced further by triage using ZNF671m in hrHPV- patients.

Keywords: ASCUS; CIN3+ detection; DNA methylation; Thinprep cytologic test; ZNF671; cervical cancer; hrHPV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Methylation / genetics
  • Female
  • Human papillomavirus 16 / genetics
  • Human papillomavirus 18 / genetics
  • Humans
  • Tumor Suppressor Proteins / genetics
  • Uterine Cervical Dysplasia* / diagnosis
  • Uterine Cervical Neoplasms* / diagnosis
  • Uterine Cervical Neoplasms* / genetics

Substances

  • ZNF671 protein, human
  • Tumor Suppressor Proteins